UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 20, 2010
PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.
(Exact name of registrant as specified in its charter)
North Carolina
(State or other jurisdiction of incorporation)
| | |
| 0-27570 | | 56-1640186 |
(Commission File Number) | | (IRS Employer ID Number) |
929 North Front Street, Wilmington, North Carolina 28401
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (910) 251-0081
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2010 annual meeting of shareholders for Pharmaceutical Product Development, Inc. was held on May 20, 2010.
At the meeting, our shareholders elected eight members to our board of directors for a term expiring at the annual meeting of shareholders in 2011, as follows:
| | | | | | |
Members | | Number of Shares
Voted For | | Number of Shares
Against or Withheld
(Includes Abstentions) | | Broker
Non-Votes |
Stuart Bondurant, M.D. | | 88,253,270 | | 7,377,549 | | 8,557,509 |
Fredric N. Eshelman, Pharm.D. | | 88,433,382 | | 7,197,437 | | 8,557,509 |
Frederick Frank | | 85,320,098 | | 10,310,721 | | 8,557,509 |
General David L. Grange | | 89,798,299 | | 5,832,520 | | 8,557,509 |
Catherine M. Klema | | 91,462,100 | | 4,168,719 | | 8,557,509 |
Terry Magnuson, Ph.D. | | 91,504,421 | | 4,126,398 | | 8,557,509 |
Ernest Mario, Ph.D. | | 87,624,422 | | 8,006,397 | | 8,557,509 |
John A. McNeill, Jr. | | 88,310,783 | | 7,320,036 | | 8,557,509 |
Our shareholders also ratified the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending 2010. The vote for such ratification was 96,149,875 shares for, 8,038,452 shares against (including abstentions) and no broker non-votes.
Item 8.01. Other Events.
On May 24, 2010, Pharmaceutical Product Development, Inc. issued a press release that its board of directors set the shareholder record date as June 1, 2010 and a distribution date of June 14, 2010 in connection with the spin-off of its wholly owned subsidiary, Furiex Pharmaceuticals, Inc. Shareholders of record will receive a pro rata dividend of one share of Furiex Pharmaceuticals, Inc. common stock for every 12 shares of PPD common stock with any fractional shares to be paid in cash. A copy of this press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
| | |
Exhibit No. | | Description |
| |
| 99.1 | | Press release dated May 24, 2010. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| | |
| | PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. |
| |
| Date: May 24, 2010 | | |
| | /s/ Daniel G. Darazsdi |
| | Daniel G. Darazsdi, |
| | Chief Financial Officer |
